2018-11-14T15:25:45-06:00 2018-06-30 420714325 RSM US LLP 100 INTERNATIONAL DRIVE SUITE 1400 BALTIMORE MD 21202 990 2017-07-01 237135845 THE FOUNDATION FIGHTING BLINDNESS INC FOUN 4104230600 7168 COLUMBIA GATEWAY DRIVE NO 100 COLUMBIA MD 21046 PATRICIA DUDLEY CHRO 4104230600 2018-11-13 1 JULIA FLANNERY CPA P00928915 4102469301 66.98.98.16 2018-11-13 09:49:03 ES P CDBA28A911E66288058FA62898B1BC86E1332D72 4EE6A31F760B3C5EA0809148B0E883CC4242B14C 2017 2019-02-21 02:37:17Z BENJAMIN YERXA 7168 COLUMBIA GATEWAY DRIVE NO 100 COLUMBIA MD 21046 82326235 0 X WWW.FIGHTBLINDNESS.ORG X 1971 MD THE MISSION OF THE FOUNDATIION FIGHTING BLINDNESS, INC. (FFB) IS TO DRIVE THE RESEARCH THAT WILL PROVIDE PREVENTIONS, TREATEMENTS AND CURES FOR PEOPLE AFFECTED BY RETINITIS PIGMENTOSA, MACULAR DEGENERATION, USHER SYNDROME, AND THE SPECTRUM OF RETINAL DEGENERATIVE DISEASES. 18 18 76 2500 0 3172 22746532 22775761 136003 255996 2186159 2441422 -478510 -508508 24590184 24964671 15462635 20785716 0 0 6755632 6824930 593653 322478 6562410 5863405 6064329 28675325 33997453 -4085141 -9032782 154220569 137901875 16294861 10783026 137925708 127118849 X THE MISSION OF THE FOUNDATION FIGHTING BLINDNESS, INC. (FFB) IS TO DRIVE THE RESEARCH THAT WILL PROVIDE PREVENTIONS, TREATMENTS AND CURES, FOR PEOPLE AFFECTED BY RETINITIS PIGMENTOSA, MACULAR DEGENERATION, USHER SYNDROME, AND THE SPECTRUM OF RETINAL DEGENERATIVE DISEASES. 0 0 22407193 20785716 165300 RESEARCH - THE FOUNDATION FIGHTING BLINDNESS, INC. (FFB) FUNDED RESEARCHERS ARE ACHIEVING REMARKABLE SUCCESS IN DISCOVERING, TESTING AND DELIVERING TO PATIENTS A WIDE RANGE OF PROMISING THERAPIES TO PREVENT, STOP THE PROGRESSION, OF, AND CURE BLINDNESS DUE TO RETINAL DEGENERATIVE DISEASES. FFB HAS ENCUMBRANCES OF $41 MILLION, NOT INCLUDED ON OUR JUNE 30 FINANCIAL REPORT, FOR ACTIVE RESEARCH PROJECTS THAT HAVE FUTURE RESEARCH MILESTONES. OUR RESEARCH OVERSIGHT COMMITTEE'S SPENDING PLAN INCLUDES SPENDING AT AN AVERAGE OF $18 MILLION ANNUALLY TO SUPPORT FUTURE RESEARCH.AS OF THE END OF OUR FY2018, FFB'S RESEARCH GRANTS PROGRAM IS FUNDING 63 GRANTS BEING CONDUCTED BY MORE THAN 110 INVESTIGATORS AT 67 INSTITUTIONS, EYE HOSPITALS AND UNIVERSITIES IN THE U.S. AND AROUND THE WORLD. A SAMPLING OF THE RESEARCH PROJECTS FUNDED ARE LISTED BELOW.- JOHN ASH, PHD, FFB-FUNDED RESEARCHER AT THE UNIVERSITY OF FLORIDA, CONDUCTED LAB RESEARCH ON EMERGING NEUROPROTECTIVE TREATMENTS INCLUDING A DRUG AND A GENE THERAPY WHICH ARE DESIGNED TO SLOW VISION LOSS FOR A BROAD RANGE OF RETINAL DEGENERATIVE DISEASES. DR. ASH IS ALSO WORKING TO REPURPOSE FDA-APPROVED THERAPIES AS VISION-SAVING TREATMENTS FOR THESE CONDITIONS.- DAVID GAMM, MD, PHD, FFB-FUNDED RESEARCHER AT THE UNIVERSITY OF WISCONSIN, MADISON, IS DEVELOPING A RETINAL PATCH, DERIVED FROM INDUCED PLURIPOTENT STEM CELLS (STEM CELLS DERIVED FROM THE BLOOD AND SKIN OF HUMANS) FOR RESTORING VISION LOST FROM A RANGE OF RETINAL DEGENERATIVE DISEASES. THE PATCH IS COMPOSED OF PHOTORECEPTORS, WHICH MAKE VISION POSSIBLE, AND RETINAL PIGMENT EPITHELIAL CELLS, WHICH PROVIDE ESSENTIAL SUPPORT FOR PHOTORECEPTORS. THE START-UP COMPANY OPSIS THERAPEUTICS HAS BEEN FORMED TO ADVANCE THE TREATMENT INTO A CLINICAL TRIAL AND OUT TO THE MARKETPLACE.- USING GENE THERAPY, FFB-FUNDED RESEARCHERS AT THE UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE AND PERELMAN SCHOOL OF MEDICINE HAVE REVERSED THE DISEASE PROCESS IN A CANINE MODEL OF BEST DISEASE, AN INHERITED FORM OF MACULAR DEGENERATION THAT CAN LEAD TO SEVERE VISION LOSS IN HUMANS. THE THERAPEUTIC EFFECT OF THE TREATMENT HAS BEEN SUSTAINED FOR AS LONG AS FIVE YEARS. RESULTS OF THE STUDY LED BY KARINA GUZIEWICZ, PHD, AND ARTUR CIDECIYAN, PHD, WERE PUBLISHED ONLINE IN THE JOURNAL PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES. 2324088 190696 PUBLIC HEALTH EDUCATION - DURING FY2018, THROUGH OUR CHATLOS FOUNDATION PUBLIC HEALTH EDUCATION PROGRAM, FFB AIMED TO CONTINUE TO PROVIDE EDUCATION AND SUPPORT TO PEOPLE AFFECTED BY RETINAL DEGENERATIVE DISEASES. TO KEEP OUR CONSTITUENTS INFORMED, FFB OPERATES A WEBSITE, BLOG AND SOCIAL MEDIA SITES; DISTRIBUTES A NEWSLETTER, ONLINE AND IN PRINT; HOSTS LOCAL, REGIONAL AND NATIONAL EDUCATIONAL SESSIONS; AND, SUPPORTS FUNDRAISING VISIONWALKS, DINING IN THE DARK DINNERS AND OTHER SPECIAL EVENTS. FFB'S WEBSITE (HTTP://WWW.FIGHTBLINDNESS.ORG) IS OUR MOST-WIDELY USED RESOURCE. IT IS AVAILABLE ALL DAY, EVERY DAY TO DISSEMINATE INFORMATION ABOUT INHERITED RETINAL DISEASES, AS WELL AS, ONGOING RESEARCH AND ADVANCES TOWARD TREATMENTS, PREVENTIONS AND CURES. CONSTITUENTS ALSO USE THE WEBSITE TO FIND A COMMUNITY OF SUPPORT AND AS A TOOL TO HELP RAISE AWARENESS AND SUPPORT FOR RETINAL DISEASE RESEARCH. IN FY2018, FFB'S WEBSITE RECEIVED APPROXIMATELY 550,000 UNIQUE VISITORS, RESULTING IN 1.3 MILLION PAGE VIEWS.INFOCUS, THE NEWSLETTER FOR FRIENDS OF THE FOUNDATION FIGHTING BLINDNESS, IS ANOTHER SIGNIFICANT WAY OF INFORMING OUR CONSTITUENTS. IT IS OFFERED IN PRINT AND ELECTRONICALLY. DURING FY2018, FFB ISSUED TWO EDITIONS OF THE NEWSLETTER, THE PRINT EDITIONS WERE CIRCULATED TO APPROXIMATELY 59,000 RECIPIENTS AND THE ELECTRONIC VERSIONS WERE EMAILED TO AN APPROXIMATELY 19,000 RECIPIENTS. FFB HELD ITS BIENNIAL NATIONAL CONFERENCE, VISIONS2018, IN SAN DIEGO, CA FROM JUNE 21-23, 2018. THE CONFERENCE BROUGHT TOGETHER LEADING VISION SCIENTISTS, ASSISTIVE TECHNOLOGIES EXPERTS, AND THE VISUALLY IMPAIRED COMMUNITY. MORE THAN 30 DISTINGUISHED PANELISTS PRESENTED, WITH APPROXIMATELY 510 PEOPLE IN ATTENDANCE FROM AROUND THE WORLD.FFB'S REGIONAL VISION SEMINARS ARE FREE, HALF-DAY EDUCATIONAL SESSIONS THAT FEATURE RESEARCH, SCIENCE AND LIFESTYLE EXPERTS HELD IN STRATEGIC LOCATIONS AROUND THE COUNTRY. FFB HOSTED EIGHT OF THESE SEMINARS DURING FY2018, WITH COLLECTIVE ATTENDANCE OF MORE THAN 1,100 PEOPLE. IN COMMUNITIES ACROSS THE NATION, FFB CHAPTERS HOSTED MORE THAN 60 EDUCATIONAL PRESENTATIONS AND NEARLY 40 SOCIAL/OUTREACH ACTIVITIES. 24731281 1 1 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 1 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 177 0 1 76 1 1 1 0 0 0 0 1 1 0 0 0 0 X 18 18 0 0 0 0 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT FL GA HI KS IL IN MA ME MD MI MN MS NH NJ NM NY NC OH OK OR PA SC TN UT VA WA WV WI AZ X X NANCY DAVENPORT CPA 4104230608 7168 COLUMBIA GATEWAY DRIVE NO 100 COLUMBIA MD 21046 X DAVID BRINT CHAIRMAN 10.00 1.00 X X 0 0 0 JOEL DAVIS VICE CHAIRMAN, MAJOR GIFTS 1.00 X X 0 0 0 EDWARD RUSSNOW VICE CHAIRMAN, DEVELOPMENT 1.00 X X 0 0 0 JONATHAN STEINBERG MD VICE CHAIRMAN, RESEARCH 1.00 1.00 X X 0 0 0 WARREN THALER VICE CHAIRMAN, BOARD DEV & COMM 1.00 X X 0 0 0 HAYNES LEA TREASURER 1.00 X X 0 0 0 YVONNE CHESTER SECRETARY 1.00 X X 0 0 0 STEVEN ALPER DIRECTOR 1.00 X 0 0 0 WILLIAM CARTY DIRECTOR 1.00 X 0 0 0 JASON FERREIRA DIRECTOR 1.00 X 0 0 0 JASON MORRIS DIRECTOR 1.00 X 0 0 0 GORDON GUND DIRECTOR - CHAIRMAN EMERITUS 1.00 1.00 X X 0 0 0 ROBERT HEIDENBERG DIRECTOR 1.00 1.00 X 0 0 0 JANNI LEHRER-STEIN DIRECTOR 1.00 X 0 0 0 BRADFORD MANNING DIRECTOR 1.00 X 0 0 0 EVAN MITTMAN DIRECTOR 1.00 X 0 0 0 KAREN PETROU DIRECTOR 1.00 X 0 0 0 MARYROSE SYLVESTER DIRECTOR 1.00 X 0 0 0 WILLIAM THOMAS SCHMIDT CEO (THRU 7/14/17) 40.00 1.00 X 278906 0 8452 BENJAMIN R YERXA CEO (BEG 10/17) 40.00 1.00 X 87474 0 6925 VALERIE NAVY-DANIELS CHIEF DEV OFFICER (THRU 2/20/18) 40.00 X 267399 0 37758 STEPHEN MARK ROSE CHIEF SCIENTIFIC OFFICER 40.00 X 238054 0 25976 PATRICIA ZILLIOX CHIEF DRUG DEV OFF (THRU 11/10/17) 1.00 40.00 X 0 224459 8612 PATRICIA DUDLEY CHIEF HUMAN RESOURCE OFFICER 40.00 X 153078 0 33966 ANNETTE HINKLE CFO (THRU 3/30/18) 40.00 1.00 X 129420 0 8266 JASON D MENZO COO (BEG 3/12/18) 40.00 1.00 X 0 0 0 HOPE KESSLER SR. DIRECTOR, MAJOR GIFTS 40.00 X 247912 0 20829 JAMES C RICHARDSON DEP CHIEF PRECLIN TRANS(THRU 2/20/18) 40.00 X 199202 0 9030 BRIAN MANSFIELD SR. VICE PRESIDENT SCIENCE 40.00 X 169991 0 34747 RHEA FARBERMAN DEPUTY CHIEF, DEVELOP (THRU 2/20/18) 40.00 X 167776 0 32003 MICHELE MERCER SR. DIRECTOR, DATABASE OPERATION 40.00 X 115723 0 23649 MARK LACHMAN DIR, MAJOR GIFTS (THRU 2/20/18) 40.00 X 121205 0 27734 MICHELE C DIVINCENZO SR. DIRECTOR, NATIONAL EVENTS 40.00 X 108725 0 18777 JOHN R CORNEILLE DIRECTOR, GIFT PLANNING 40.00 X 108324 0 13563 TIMOTHY SCHOEN DIR, CONSTIT OUTREACH (THRU 7/18/17) 40.00 X 127844 0 27128 2521033 224459 337415 15 0 1 0 CONCORD LITHO GROUP 92 OLD TURNPIKE ROAD CONCORD NH 03301 PRINTING/MAIL HOUSE 266228 BLACKBAUD PO BOX 930256 ATLANTA GA 31193 ONLINE FUNDRAISING FEES 241978 NNE MARKETING 1666 MASSACHUSETTS AVE SUITE 14 LEXINGTON MA 02420 MEMBERSHIP CONSULTANT 227000 SPENCER STUART PO BOX 98991 CHICAGO IL 60693 CEO SERACH AGENCY 178264 HARRIS PLUS LLC 8516 RAINSWOOD DRIVE LANDOVER MD 20785 PRINTING/MAIL HOUSE 159643 9 185099 7053388 15537274 725651 22775761 CONFERENCE FEES & SPON 900099 190696 190696 CONTRACT REVENUE 900099 65300 65300 255996 4842090 4842090 626 626 32473 0 32473 32473 32473 53782787 56183455 -2400668 -2400668 -2400668 534697 7053388 1178109 -643412 -643412 FFB CRI SERVICE FEES 900099 100000 100000 1805 1805 101805 24964671 355996 0 1832914 19435340 19435340 1350376 1350376 2305052 631642 462982 1210428 3527556 971576 703743 1852237 68018 21470 14917 31631 532371 125288 115009 292074 391933 102128 76491 213314 24763 9763 9480 5520 38286 34210 4076 322478 322478 316854 296850 20004 807459 430254 201390 175815 1130948 161256 408751 560941 394541 25017 47485 322039 631184 81710 113390 436084 423324 159590 35148 228586 1082637 905000 96513 81124 235974 120577 38482 76915 186940 49106 31893 105941 PRINTING AND PRODUCTION 791419 151188 17028 623203 33997453 24731281 2703762 6562410 5745318 7687395 59090 16755072 35451197 29204636 2672556 450470 500000 695130 583113 5912774 4528031 1558178 1384743 100863588 73061630 6740654 434858 8274816 154220569 137901875 3349297 1637741 10446066 6727999 826220 526096 1673278 1891190 16294861 10783026 X 23730443 28938419 110938517 94923682 3256748 3256748 137925708 127118849 154220569 137901875 X -9032782 -1863882 2 89803 X 0 1 X 1 0 X 37077623 56098521 68515510 22746532 22775761 207213947 37077623 56098521 68515510 22746532 22775761 207213947 66444849 140769098 2787360 2753831 4764598 4320989 4875189 19501967 107417 102294 102691 100091 101805 514298 227230212 4218030 0.61950 0.60690 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: FFB CRI SERVICE FEES - 2013 AMOUNT: $ 99,900. 2014 AMOUNT: $ 100,000. 2015 AMOUNT: $ 99,996. 2016 AMOUNT: $ 99,996. 2017 AMOUNT: $ 100,000. RESEARCH PATENT - 2013 AMOUNT: $ 7,517. MISCELLANEOUS - 2014 AMOUNT: $ 2,294. 2015 AMOUNT: $ 2,695. 2016 AMOUNT: $ 95. 2017 AMOUNT: $ 1,805. 3256748 11279 9028 2251 3256748 3190000 66748 17173 15012 2161 3256748 500000 2690000 23270 21049 2221 3190000 500000 30311 28140 2171 500000 500000 21205 19117 2088 500000 1.00000 0 0 867698 635906 231792 1467646 1237942 229704 3577430 2654183 923247 1384743 DEFERRED COMPENSATION FUND 773211 BENEFICIAL INTERESTS IN REMAINDER TRUSTS 6209277 CHARITABLE GIFT ANNUITY 941273 DUE FROM RELATED PARTY 351055 8274816 CHARITABLE GIFT ANNUITY OBLIGATION 739537 DEFERRED COMPENSATION OBLIGATION 773211 DEFERRED RENT 378442 1891190 X 23152206 -1863882 173049 13266197 11575364 11576842 296850 13090979 13387829 24964671 32502110 173049 11719437 11892486 20609624 296850 13090979 13387829 33997453 PART V, LINE 4: EARNINGS CAN BE USED FOR OPERATIONS; PRINCIPAL IS PERMANENTLY RESTRICTED. PART X, LINE 2: THE FOUNDATION PERFORMED AN EVALUATION OF ITS UNCERTAINTY IN INCOME TAX FOR THE YEARS ENDED JUNE 30, 2018 AND 2017, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS. THE FOUNDATION FOLLOWS THE ACCOUNTING STANDARD ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES, WHICH ADDRESSES THE DETERMINATION OF WHETHER TAX BENEFITS CLAIMED OR EXPECTED TO BE CLAIMED ON A TAX RETURN SHOULD BE RECORDED IN THE FINANCIAL STATEMENTS. UNDER THIS POLICY, THE FOUNDATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WOULD BE SUSTAINED ON EXAMINATION BY TAXING AUTHORITIES, BASED ON THE TECHNICAL MERITS OF THE POSITION. MANAGEMENT HAS EVALUATED THE FOUNDATION'S TAX POSITIONS AND HAS CONCLUDED THAT THE FOUNDATION HAS TAKEN NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH PROVISIONS OF THIS GUIDANCE. THE FOUNDATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS FOR THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE JUNE 30, 2015. PART XI, LINE 2D - OTHER ADJUSTMENTS: REVENUE FROM AFFILIATE INCLUDED ON CONSOLIDATED FINANCIAL STATEMENTS 13,266,197. PART XI, LINE 4B - OTHER ADJUSTMENTS: ELIMINATION ENTRY INCLUDED ON FINANCIAL STATEMENTS 13,090,979. PART XII, LINE 2D - OTHER ADJUSTMENTS: EXPENSES FROM AFFILIATE INCLUDED ON CONSOLIDATED FINANCIAL STATEMENTS 11,809,240. GRANT REFUNDS -89,803. PART XII, LINE 4B - OTHER ADJUSTMENTS: ELIMINATION ENTRY INCLUDED ON FINANCIAL STATEMENTS 13,090,979. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 1125376 NORTH AMERICA 0 0 GRANTMAKING 150000 SOUTH ASIA 0 0 GRANTMAKING 75000 0 0 0 0 0 0 1350376 0 1350376 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 100000 CHECK 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 65000 CHECK 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 860376 CHECK 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 100000 CHECK 0 NORTH AMERICA RESEARCH 75000 CHECK 0 NORTH AMERICA RESEARCH 75000 CHECK 0 SOUTH ASIA RESEARCH 75000 CHECK 0 7 0 0 0 0 0 0 0 PART I, LINE 2: EACH GRANTEE IS REQUIRED TO SUBMIT A YEARLY SCIENTIFIC PROGRESS REPORT, WHICH IS REVIEWED BY THE FFB SCIENCE STAFF AND COMPARED WITH THE PROPOSED MILESTONES SUBMITTED WITH THE ORIGINAL GRANT APPLICATION. ATTENTION IS ALSO GIVEN TO THE PLAN FOR EXPERIMENTS TO BE PERFORMED IN THE COMING YEAR. ANY PROBLEMS OR ISSUES IDENTIFIED BY THE GRANTEE AND/OR FFB SCIENTIFIC STAFF ARE RESOLVED TO OUR MUTUAL SATISFACTION; HOWEVER, IF A CONSENSUS CANNOT BE REACHED OR IF THE APPARENT PROGRESS IS NOT SATISFACTORY IN THE OPINION OF FFB SCIENTIFIC STAFF, AFTER CONSULTATION WITH MEMBERS OF THE FFB SCIENTIFIC ADVISORY BOARD, THE GRANT IS TERMINATED WITH A SHORT PHASE OUT PERIOD. EACH GRANTEE IS REQUIRED TO SUBMIT A YEARLY FINANCIAL REPORT DETAILING GRANT EXPENDITURES ACCORDING TO THEIR FFB APPROVED GRANT BUDGET. SCIENCE STAFF REVIEW EACH FINANCIAL REPORT FOR ADHERENCE TO BUDGETED EXPENDITURES IN EACH CATEGORY. WITH PROPER DOCUMENTATION AND IF DETERMINED APPROPRIATE, REQUESTS FOR CARRYOVER OF UNEXPENDED FUNDS TO THE NEXT FISCAL YEAR ARE REVIEWED AND APPROVED ON A CASE-BY-CASE BASIS. X X X X X X 1 THE HERITAGE COMPANY 2402 WILDWOOD AVENUE NORTH LITTLE ROCK AR 72120 TELEMARKETING FUNDRAISING COUNSEL 0 123502 70478 53024 NNE MARKETING 754 MASSACHUSETTS AVENUE ARLINGTON MA 02476 FUNDRAISING COUNSEL 0 0 227000 -227000 VENTUROUS LLC 269 S BEVERLY DRIVE 1317 BEVERLY HILLS CA 90212 EVENT FUNDRAISING COUNSEL 0 0 25000 -25000 123502 322478 -198976 AL AK AZ AR CA CO CT FL GA HI IL IN KS ME MD MA MI MN MS NC NH NJ NM NY OH OK OR PA SC TN UT VA WA WV WI NY DINNER 852895 702895 150000 38239 98876 137900 8279 ST. LOUIS DINNER 429480 371520 57960 7297 67800 4214 59 6305710 5978973 326737 379976 277178 43332 115018 7588085 7053388 534697 425512 443854 181232 127511 1178109 -643412 1 AUGUSTA UNIV RESEARCH INSTITUTE 1120 15TH STREET AUGUSTA GA 30912 586002053 501(C)(3) 100000 0 RESEARCH DUKE UNIVERSITY MEDICAL CENTER 2200 W MAINE STREET DURHAM NC 27705 560532129 501(C)(3) 99999 0 RESEARCH FLORIDA STATE UNIVERSITY 600 W COLLEGE AVENUE TALLAHASSEE FL 32306 596152180 501(C)(3) 100000 0 RESEARCH FOUNDATION FIGHTING BLINDNESS CLINICAL RESEARCH INSTITUTE 7168 COLUMBIA GATEWAY DRIVE COLUMBIA MD 21046 450524687 501(C)(3) 12990979 0 RESEARCH JOHNS HOPKINS UNIVERSITY 600 NORTH WOLFE STREET BALTIMORE MD 21287 520595110 501(C)(3) 109814 0 RESEARCH MASSACHUSETTS EYE AND EAR INFIRMARY 243 CHARLES STREET BOSTON MA 02114 042103591 501(C)(3) 1339235 0 RESEARCH MOLECULAR INSIGHT RESEARCH FOUNDATION 8635 WEST 3RD LOS ANGELES CA 90048 205329822 501(C)(3) 100000 0 RESEARCH OREGON HEALTH AND SCIENCE UNIVERSITY 3375 TERWILLIGER BOULEVARD SW PORTLAND OR 97201 237083114 501(C)(3) 318055 0 RESEARCH REGENTS UNIV OF CALIFORNIA 10889 WILSHIRE BLVD LOS ANGELES CA 90095 943067788 501(C)(3) 100000 0 RESEARCH STANFORD UNIVERSITY SCHOOL OF MEDICINE SUMC RM L-331 STANFORD CA 94305 941156365 501(C)(3) 100000 0 RESEARCH UNIV OF N TX HEALTH AND SCIENCE CENTER 3500 CAMP BOWIE BLVD FORT WORTH TX 76107 756064033 501(C)(3) 75000 0 RESEARCH UNIVERSITY CALIFORNIA SAN FRANCISCO 100 STEIN PLAZA LOS ANGELES CA 90095 956006143 501(C)(3) 498174 0 RESEARCH UNIVERSITY HOSPITALS UH GRANTS DEPT 781686 PO BOX 78000 DETROIT MI 48278 341567805 501(C)(3) 1035335 0 RESEARCH UNIVERSITY OF CALIFORNIA BERKELEY 2150 SHATTUCK AVENUE BERKELEY CA 94720 946002123 501(C)(3) 125699 0 RESEARCH UNIVERSITY OF MICHIGAN 100 WALL STREET ANN ARBOR MI 48105 386006309 501(C)(3) 99973 0 RESEARCH UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 232810852 501(C)(3) 1658533 0 RESEARCH UNIVERSITY OF PITTSBURGH 123 UNIVERSITY PLACE PITTSBURGH PA 15213 250965591 501(C)(3) 100000 0 RESEARCH UNIVERSITY OF ROCHESTER 513 HYLAND BUILDING PO BOX 270140 ROCHESTER NY 14627 160743209 501(C)(3) 99777 0 RESEARCH UNIVERSITY OF SOUTHERN CALIFORNIA 2001 SOTO STREET LOS ANGELES CA 90089 951642394 501(C)(3) 43000 0 RESEARCH UNIVERSITY OF UTAH 75 SOUTH 2000 EAST SALT LAKE CITY UT 84112 876000525 501(C)(3) 100000 0 RESEARCH UNIVERSITY OF WASHINGTON 1100 45TH ST NE SEATTLE WA 98105 943079432 501(C)(3) 98767 0 RESEARCH UNIVERSITY OF WASHINGTON 1959 NE PACIFIC STREET SEATTLE WA 98195 916001537 501(C)(3) 43000 0 RESEARCH UNIVERSITY OF WISCONSIN 21 NORTH PARK STREET MADISON WI 53715 390743975 501(C)(3) 100000 0 RESEARCH 23 0 PART I, LINE 2: EACH GRANTEE IS REQUIRED TO SUBMIT A YEARLY SCIENTIFIC PROGRESS REPORT, WHICH IS REVIEWED BY THE FFB SCIENCE STAFF AND COMPARED WITH THE PROPOSED MILESTONES SUBMITTED WITH THE ORIGINAL GRANT APPLICATION. ATTENTION IS ALSO GIVEN TO THE PLAN FOR EXPERIMENTS TO BE PERFORMED IN THE COMING YEAR. ANY PROBLEMS OR ISSUES IDENTIFIED BY THE GRANTEE AND/OR FFB SCIENTIFIC STAFF ARE RESOLVED TO OUR MUTUAL SATISFACTION; HOWEVER, IF A CONSENSUS CANNOT BE REACHED OR IF THE APPARENT PROGRESS IS NOT SATISFACTORY IN THE OPINION OF FFB SCIENTIFIC STAFF, AFTER CONSULTATION WITH MEMBERS OF THE FFB SCIENTIFIC ADVISORY BOARD, THE GRANT IS TERMINATED WITH A SHORT PHASE OUT PERIOD. EACH GRANTEE IS REQUIRED TO SUBMIT A YEARLY FINANCIAL REPORT DETAILING GRANT EXPENDITURES ACCORDING TO THEIR FB APPROVED GRANT BUDGET. SCIENCE STAFF REVIEW EACH FINANCIAL REPORT FOR ADHERENCE TO BUDGETED EXPENDITURES IN EACH CATEGORY. WITH PROPER DOCUMENTATION AND IF DETERMINED APPROPRIATE, REQUESTS FOR CARRYOVER OF UNEXPENDED FUNDS TO THE NEXT FISCAL YEAR ARE REVIEWED AND APPROVED ON A CASE-BY-CASE BASIS. X 1 1 X X X X X 1 0 0 0 0 0 0 0 0 WILLIAM THOMAS SCHMIDT CEO (THRU 7/14/17) 200347 0 0 0 78559 0 5894 0 2558 0 287358 0 0 0 VALERIE NAVY-DANIELS CHIEF DEV OFFICER (THRU 2/20/18) 266367 0 0 0 1032 0 8100 0 29658 0 305157 0 0 0 STEPHEN MARK ROSE CHIEF SCIENTIFIC OFFICER 235158 0 0 0 2896 0 7232 0 18744 0 264030 0 0 0 PATRICIA ZILLIOX CHIEF DRUG DEV OFF (THRU 11/10/17) 0 207377 0 0 0 17082 0 6297 0 2315 0 233071 0 0 PATRICIA DUDLEY CHIEF HUMAN RESOURCE OFFICER 133407 0 0 0 19671 0 4812 0 29154 0 187044 0 0 0 HOPE KESSLER SR. DIRECTOR, MAJOR GIFTS 236119 0 7100 0 4693 0 2472 0 18357 0 268741 0 0 0 JAMES C RICHARDSON DEP CHIEF PRECLIN TRANS(THRU 2/20/18 198788 0 0 0 414 0 5763 0 3267 0 208232 0 0 0 BRIAN MANSFIELD SR. VICE PRESIDENT SCIENCE 168984 0 0 0 1007 0 5339 0 29408 0 204738 0 0 0 RHEA FARBERMAN DEPUTY CHIEF, DEVELOP (THRU 2/20/18) 165452 0 1000 0 1324 0 5201 0 26802 0 199779 0 0 0 TIMOTHY SCHOEN DIR, CONSTIT OUTREACH (THRU 7/18/17) 51589 0 0 0 76255 0 1677 0 25451 0 154972 0 0 0 PART I, LINE 1A GROSS UP PAYMENTS WERE RECEIVED BY RHEA FARBERMAN AND MICHELE DIVINCENZO DURING THE CALENDAR YEAR. THESE GROSS UP PAYMENTS WERE INCLUDED IN TAXABLE COMPENSATION. PART I, LINE 4A MR. SCHOEN RECEIVED A SEVERANCE PAYMENT DURING THE CALENDAR YEAR. THE PAYMENT IS INCLUDED IN PART VII, COLUMN D AND SCHEDULE J, PART II, COLUMN BIII. THE TERMS AND CONDITIONS OF THE CONFIDENTIAL AGREEMENT ARE AVAILABLE TO THE INTERNAL REVENUE SERVICE UPON REQUEST. X 43 451648 FAIR MARKET VALUE X AUCTION ITEMS 1 234139 FAIR MARKET VALUE X EVENT ITEMS 1 39864 FAIR MARKET VALUE 0 1 1 PART I, COLUMN (B): THE NUMBER IN THIS COLUMN REPRESENTS THE NUMBER OF CONTRIBUTIONS. PART I, LINE 32B: WHEN DONATED STOCK IS RECEIVED, OUR BROKER MERRILL LYNCH IMMEDIATELY CONVERTS THESE CONTRIBUTIONS INTO CASH. FORM 990, PART VI, SECTION A, LINE 6 MEMBERS OF FFB ARE KNOWN AS NATIONAL TRUSTEES. THE QUALIFICATIONS AND ELIGIBILITY FOR MEMBERSHIP AND THE MANNER OF ADMISSION INTO MEMBERSHIP IS PRESCRIBED BY RESOLUTION OF THE BOARD OF DIRECTORS. THE NATIONAL TRUSTEES ARE ENTITLED TO VOTE ON ELECTION OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7A DURING THE ANNUAL MEETING OF THE NATIONAL TRUSTEES, MEMBERS OF THE BOARD OF DIRECTORS ARE ELECTED. FORM 990, PART VI, SECTION B, LINE 11B DATA TO PREPARE THE FEDERAL FORM 990 IS PROVIDED TO OUR OUTSIDE ACCOUNTING FIRM FOR PREPARATION AND GUIDANCE. AFTER IT HAS BEEN COMPLETED, A DRAFT OF THE FEDERAL FORM 990 IS REVIEWED BY THE SENIOR DIRECTOR OF FINANCE AND CHIEF OPERATING OFFICER. WITH THE SENIOR DIRECTOR OF FINANCE'S APPROVAL, THE DRAFT FEDERAL FORM 990 IS THEN MADE AVAILABLE TO ALL BOARD MEMBERS. ALL BOARD MEMBERS ARE INVITED TO ATTEND A SPECIAL MEETING OF THE FINANCE COMMITTEE TO REVIEW THE FEDERAL FORM 990. A FINAL DRAFT IS MADE AVAILABLE TO ALL BOARD MEMBERS BEFORE FILING. FORM 990, PART VI, SECTION B, LINE 12C IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON (INCLUDING OFFICERS, DIRECTORS, AND KEY EMPLOYEES) MUST DISCLOSE, IN WRITING PRIOR TO ANY DISCUSSION OR VOTE UPON A PROPOSAL, THE EXISTENCE AND NATURE OF HIS OR HER PERSONAL INTEREST TO THE CHAIR OF THE BOARD AND CHAIR OF THE BOARD COMMITTEE CONSIDERING THE PROPOSED TRANSACTION OR ARRANGEMENT. AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE FINANCIAL INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS, AND IF SO, WHETHER THERE IS A COMPELLING REASON TO RECOMMEND TO THE BOARD THAT THE CONFLICT OF INTEREST POLICY BE OVERRIDDEN. A QUORUM IS NEEDED FOR VOTING AND THE VOTE TO OVERRIDE SHALL BE BY MAJORITY AND DULY NOTED IN THE MINUTES. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE AND THE BOARD OF DIRECTORS APPROVES THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER. THE COMPENSATION COMMITTEE APPROVES THE COMPENSATION OF THE OTHER CHIEF OFFICERS. ON A ROUTINE BASIS, EXTERNAL DATA PROVIDED BY OUTSIDE EXPERT COMPENSATION CONSULTANTS IS USED TO MEASURE REASONABLENESS OF SALARIES TO THE MARKET PLACE AND RESULTS ARE COMMUNICATED BY OUTSIDE CONSULTANTS TO THE BOARD CHAIR/COMPENSATION COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 FFB'S FEDERAL FORM 990 AND CONSOLIDATED AUDITED FINANCIAL STATEMENTS ARE AVAILABLE AT WWW.FIGHTBLINDNESS.ORG. OTHER PUBLIC DOCUMENTS INCLUDING THE CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST THROUGH THE CONTACT INFORMATION DISCLOSED ON FFB'S WEB SITE. THESE DOCUMENTS ARE AVAILABLE FOR THE SAME PERIOD OF DISCLOSURE AS SET FORTH IN SECTION 6104(D). FORM 990, PART VII, SECTION A: FFB ACTS AS THE COMMON PAYMASTER FOR THE FOUNDATION FIGHTING BLINDNESS CLINICAL RESEARCH INSTITUTE, A RELATED ORGANIZATION. FORM 990, PART XI, LINE 9: GRANT REFUNDS 89,803. FOUNDATION FIGHTING BLINDNESS CLINICAL RESEARCH INSTITUTE 7168 COLUMBIA GATEWAY DRIVE SUITE 1 COLUMBIA MD 21046 450524687 FUNDS RESEARCH AND CLINICAL TRIALS TO FIND TREATMENTS FOR RETINAL DISEASES DE 501(C)(3) LINE 12A, I FOUNDATION FIGHTING BLINDNESS INC 1 MACULAR DEGENERATION INTERNATIONAL INC 7168 COLUMBIA GATEWAY DRIVE SUITE 1 COLUMBIA MD 21046 363923922 FUNDRAISING IL 501(C)(3) LINE 7 FOUNDATION FIGHTING BLINDNESS INC 1 NATIONAL RETINITIS PIGMENTOSA FOUNDATION INC 7168 COLUMBIA GATEWAY DRIVE SUITE 1 COLUMBIA MD 21046 522072391 FUNDRAISING MD 501(C)(3) LINE 12A, I FOUNDATION FIGHTING BLINDNESS INC 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 FOUNDATION FIGHTING BLINDNESS CLINICAL RESEARCH INSTITUTE B 12990979 FAIR MARKET VALUE FOUNDATION FIGHTING BLINDNESS CLINICAL RESEARCH INSTITUTE L 100000 FAIR MARKET VALUE FOUNDATION FIGHTING BLINDNESS CLINICAL RESEARCH INSTITUTE O 369024 FAIR MARKET VALUE